Hiromi Abe‐Chayama

发表

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease

M. Imamura, N. Hiraga, K. Chayama, 2018, Journal of Gastroenterology.

Highly multiplexed CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors for inactivation of hepatitis B virus

Tetsushi Sakuma, Kazuaki Chayama, K. Chayama, 2016, Genes to cells : devoted to molecular & cellular mechanisms.

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.

M. Imamura, N. Hiraga, K. Chayama, 2018, Virology.

The Association between Serum Cytokine and Chemokine Levels and Antiviral Response by Entecavir Treatment in Chronic Hepatitis B Patients

M. Imamura, K. Chayama, D. Miki, 2018, Antiviral therapy.

Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice

M. Imamura, N. Hiraga, K. Chayama, 2019, Journal of Gastroenterology.

Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study

M. Imamura, K. Chayama, D. Miki, 2018, Antiviral therapy.

Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy

M. Imamura, K. Chayama, D. Miki, 2020, Journal of medical virology.

Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection

M. Imamura, N. Hiraga, K. Chayama, 2016, Journal of Gastroenterology.

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

T. Taniguchi, M. Imamura, N. Hiraga, 2017, Antimicrobial Agents and Chemotherapy.

Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP

K. Chayama, C. Tateno, Takuro Uchida, 2019, Scientific Reports.

Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients

M. Imamura, K. Chayama, Shinji Tanaka, 2021, Journal of Infection.

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.

M. Imamura, N. Hiraga, K. Chayama, 2017, The Journal of general virology.

Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.

M. Imamura, K. Chayama, D. Miki, 2020, The Journal of infectious diseases.

Comparative study on the replication of HCV1b genome between wild‐type and cell culture‐adaptive mutant in regard to sensitivities against anti‐HCV drugs

M. Imamura, K. Chayama, M. Hijikata, 2019, Microbiology and immunology.

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

M. Imamura, N. Hiraga, K. Chayama, 2018, The Journal of general virology.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.

M. Imamura, K. Chayama, D. Miki, 2018, Biochemical and biophysical research communications.

A novel cDNA‐uPA/SCID/Rag2−/−/Jak3−/− mouse model for hepatitis virus infection and reconstruction of human immune system

M. Imamura, K. Chayama, H. Ohdan, 2021, Journal of viral hepatitis.

Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

M. Imamura, N. Hiraga, K. Chayama, 2017, PloS one.

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

M. Imamura, K. Chayama, D. Miki, 2020, Therapeutic advances in medical oncology.

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

M. Imamura, K. Chayama, D. Miki, 2017, Journal of Gastroenterology.

Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA.

M. Imamura, K. Chayama, Hiromi Abe-Chayama, 2022, The Journal of general virology.

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.

M. Imamura, K. Chayama, M. Hijikata, 2021, Biochemical and biophysical research communications.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

M. Imamura, K. Chayama, M. Hijikata, 2019, The Journal of general virology.

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice

M. Imamura, N. Hiraga, K. Chayama, 2017, Antimicrobial Agents and Chemotherapy.

Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection—Pilot study

M. Imamura, K. Chayama, D. Miki, 2020, Journal of viral hepatitis.

CTL‐associated and NK cell‐associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients

M. Imamura, N. Hiraga, K. Chayama, 2018, Journal of viral hepatitis.

Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

M. Imamura, K. Chayama, D. Miki, 2021, Journal of viral hepatitis.

In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism

M. Imamura, K. Chayama, D. Miki, 2020, Molecular medicine reports.

Deficiency of SCAP inhibits HBV pathogenesis via activation of the interferon signaling pathway.

K. Chayama, G. N. Makokha, Hiromi Abe-Chayama, 2023, Virology.

HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL.

M. Imamura, K. Chayama, T. Fujita, 2022, Journal of Infectious Diseases.

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

M. Imamura, K. Chayama, M. Kohara, 2023, Hepatology.

Pan‐genotypic cell culture system for propagation of hepatitis C virus clinical isolates

K. Chayama, C. N. Hayes, Hiromi Abe‐Chayama, 2016, Hepatology.